Abstract: Compositions for treatment or prevention of synovitis are provided. The compositions contain a therapeutically effective amount of at least one of oleuropein, rutin or curcumin and preferably contain at least oleuropin. Methods for treatment or prevention of synovitis are also provided, and the methods include administering such compositions. The compositions can additionally include one or more of quercetin, hydroxytyrosol or vitamin D.

Abstract: The present invention relates to use of a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and quercetin and/or derivative for maintenance of joint health or prevention or treatment of joint disorders in an individual. In particular, the invention relates to a composition comprising an effective amount of a combination of oleuropein and/or metabolite thereof and quercetin and/or derivative for use to prevent or treat cartilage degeneration in an individual.

Abstract: The invention herein relates generally to enhancing the survival and activity of probiotic Lactobacillus reuteri strains in mammals by pre-conditioning L. reuteri with GOS during cultivation and to a surprisingly high symbiotic effect of such a pre-conditioned probiotic L. reuteri strain when administered together with GOS further added in the composition. The invention therefore comprises methods for cultivating and manufacturing probiotic L. reuteri strains, and preparing products containing such pre-conditioned strains in combination with additional amounts of GOS. In more detail the present invention relates to a probiotic composition comprising a probiotic L. reuteri strain, obtained by a step of growing the bacteria in a medium comprising GOS, and administering the pre-conditioned bacteria together with further GOS in the final product. The inventors have found that such method induces surprisingly high and unexpected symbiotic beneficial effects of the probiotic bacteria in the gastrointestinal tract.

Abstract: A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail.

Abstract: A method of preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including orally administering at least one of oleuropein or metabolite thereof to an individual before, during and/or after the exercise. A unit dosage form contains at least one of oleuropein or metabolite thereof in an amount effective for administration of the unit dosage form before, during and/or after exercise to thereby prevent or treat muscle fatigue from the exercise and/or for resistance to muscle fatigue from exercise. A method of making a composition for preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including adding an effective amount of at least one of oleuropein or metabolite thereof to at least one ingredient selected from the group consisting of protein, carbohydrate, and fat.

Abstract: The present invention relates to a probiotic Lactobacillus reuteri strain obtained by growing the bacteria in a medium comprising galacto-oligosaccharides (GOS), so called pre-conditioning. The pre-conditioning method provides boosting effects of the probiotic L. reuteri strain, such as improved mineral absorption, in the gastrointestinal tract. The invention comprises methods for manufacturing and cultivating probiotic Lactobacillus reuteri strains, and products and first and second medical uses of such strains.

Abstract: The invention relates to the use of composition comprising sialylated and fucosylated human milk oligosaccharides (HMOs) for enhancing bone development and/or bone strength, preferably a nutritional composition for infants or young children.

Abstract: A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having ?-glycosidase activity or a ?-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both ?-glycosidase activity and esterase activity or an enzyme having both ?-glycosidase activity and esterase activity, (iv) a first probiotic having ?-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having ?-glycosidase activity and an esterase, (vi) a ?-glycosidase and a probiotic having esterase activity and (vii) a ?-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein.

Abstract: A composition contains at least one probiotic or enzyme selected from the group consisting of (i) a probiotic having ?-glycosidase activity or a ?-glycosidase, (ii) a probiotic having esterase activity or an esterase, (iii) a probiotic having both ?-glycosidase activity and esterase activity or an enzyme having both ?-glycosidase activity and esterase activity, (iv) a first probiotic having ?-glycosidase activity and a second probiotic having esterase activity, (v) a probiotic having ?-glycosidase activity and an esterase, (vi) a ?-glycosidase and a probiotic having esterase activity and (vii) a ?-glycosidase and an esterase. The at least one probiotic can form one or more of oleuropein aglycone, elenolic acid, hydroxytyrosol acetate or hydroxytyrosol from oleuropein. The composition can comprise oleuropein.

Abstract: The present invention relates generally to probiotics, in particular probiotics capable of bio-converting olive polyphenols. The invention relates to a method of selecting a probiotic strain or probiotic strain mixture. Further aspects of the invention include the use of a probiotic strain to increase the bio-efficacy of olive polyphenols and a composition comprising a probiotic strain for use in the potentiation of a therapeutic effect and/or a prophylactic effect of oleuropein.

Abstract: A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to decrease muscle fatigue in an individual who participates in at least one of 1) resistance exercise, 2) anaerobic or repeated sprint-type exercise, or 3) endurance exercise. Preferably, the combination of calcium and at least one of oleuropein or metabolite thereof is administered to the individual less than two hours before the exercise, and/or during the exercise, and/or less than two hours after the exercise.

Abstract: A method of preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including orally administering at least one of oleuropein or metabolite thereof to an individual before, during and/or after the exercise. A unit dosage form contains at least one of oleuropein or metabolite thereof in an amount effective for administration of the unit dosage form before, during and/or after exercise to thereby prevent or treat muscle fatigue from the exercise and/or for resistance to muscle fatigue from exercise. A method of making a composition for preventing or treating muscle fatigue from exercise and/or for resistance to muscle fatigue from exercise, the method including adding an effective amount of at least one of oleuropein or metabolite thereof to at least one ingredient selected from the group consisting of protein, carbohydrate, and fat.

Abstract: 1. Use of a compound having the formula (1) (2) (3) or (4) or combinations thereof, for use in promotion of bone growth and/or prevention and/or treatment of bone disorders associated to bone growth impairment wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: Use of a compound having the formula (1), (2), (3) or (4) or combinations thereof, for use in maintenance of bone health and/or prevention, and/or treatment of bone disorders associated to unbalanced bone catabolism wherein R1, R2, R3, R4, R5 and R6 are independently a long chain fatty acid having between 16 and 20 carbons.

Abstract: A combination of calcium and at least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is (i) improved mitochondrial calcium uptake in muscle cells, (ii) improved utilization of calcium in muscle cells, (iii) increased mitochondrial energy in muscle cells, (iv) improvement in at least one of muscle functionality, muscle performance, or muscle strength, (v) decreased muscle fatigue, (vi) increased mobility, and/or (vii) treatment of a muscle disorder linked to calcium depletion or deficiency. The individual can be at least one of an aging subject; an elderly subject; a subject with muscle fatigue or muscle weakness; a subject with impaired mobility; a frail subject; a pre-frail subject; a sarcopenic subject; a subject recovering from pre-frailty, frailty, sarcopenia or impaired mobility; a subject undergoing physical rehabilitation; a sportsman; or a pet.

Abstract: At least one of oleuropein or metabolite thereof can be orally administered to an individual in an amount effective to achieve at least one result that is one or more of (i) improvement in a physiological state linked to metabolic fatigue in one or more cells, (ii) increased mitochondrial energy and mitochondrial calcium uptake in one or more cells, and/or (iii) treatment or prevention of a calcium deficiency/depletion disorder. Additionally or alternatively, the method can treat or prevent a mitochondria-related disease or a condition associated with altered mitochondrial function in an individual in need thereof or at risk thereof.

Abstract: A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail.

Abstract: The present invention relates to use of a composition for maintenance of bone and/or cartilage health or prevention, alleviation and/or treatment of bone and/or cartilage disorders.

Abstract: A method of treating or preventing impaired mobility in an older adult includes administering to the older adult an effective amount of a composition containing at least one ingredient for cognitive ability, at least one ingredient for muscle and/or bone quality, and at least one ingredient for joint quality and/or functionality. The older adult can be an elderly individual and/or can have a condition that is one or more of frailty, pre-frailty, sarcopenia, recovering from sarcopenia, malnutrition, at risk of malnutrition, undergoing rehabilitation, and being scheduled to undergo rehabilitation, disorders impacting mobility such as osteoporosis, osteoarthritis, pre-osteoarthritis, osteopenia, cognitive decline. In a non-limiting example of the composition, the at least one ingredient for muscle and/or bone quality and the at least one ingredient for joint quality include a protein source, omega-3 fatty acids, and a polyphenol.

Abstract: A composition contains at least one of homovanillyl alcohol (HVA) or its previously unidentified isomer (isoHVA). Additionally or alternatively, the composition contains a precursor of HVA and/or isoHVA (e.g., hydroxytyrosol, oleuropein aglycone, oleuropein, demethyloleuropein, oleuroside, verbascoside or mixtures thereof) and also contains at least one probiotic and/or at least one enzyme which convert the precursor to HVA and/or isoHVA in vivo (and/or an intermediate compound then subjected to methylation in vivo to form HVA and/or isoHVA). The composition can be administered to an individual to treat or reduce incidence of impaired mobility in an older adult; stimulate bone formation and/or inhibit bone resorption; treat or reduce incidence of synovitis in an individual in need or at risk thereof; treat or reduce incidence of articular cartilage degradation subsequent to synovitis in an individual having or recovering from synovitis; or treat or reduce incidence of cartilage breakdown.